Federated learning AI platform for biomedical research. Trains AI models on sensitive hospital data without compromising privacy. Focuses on oncology and patient stratification.
Recursion Pharmaceuticals
AI-first drug discovery company combining biological imaging, machine learning, and automated labs to identify therapeutic candidates at scale. Partnerships with Bayer and Roche.
Vendor snapshot
Editorial review
This review is written by the directory and is kept separate from company-managed profile content.The Recursion OS — combining massive imaging datasets with ML — is one of the most sophisticated drug discovery infrastructures built. Rare disease and oncology pipeline is advancing.
Pricing
- Publicly traded (RXRX); partnership agreements
Integrations
Explore more Drug Discovery & Research
Deep learning platform (AtomNet) for structure-based small molecule drug discovery. Screens trillions of compounds against disease targets. 250+ research partnerships.
End-to-end AI drug discovery platform (Pharma.AI). One of the first companies to have an AI-designed drug enter human clinical trials. Focuses on oncology and fibrosis.
Genomics’ Mystra is an AI-enabled human genetics platform for drug target discovery and validation, offered with self-serve SaaS and managed options.